A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

This setup looks somewhat better than a typical efficacy-driven oncology Phase 2 because the listed primary outcomes are early safety endpoints: DLT and MTD within the first 21 days, not a hard efficacy hurdle like ORR, PFS, or OS. In untreated stage IV NSCLC, the PD-1 plus chemotherapy backbone is already a plausible platform, so the key question is whether adding anti-LAG-3 HLX26 keeps toxicity acceptable. That is not trivial: triplet immunochemotherapy can raise overlapping immune and cytotoxic adverse-event risk, and first-line metastatic NSCLC is clinically heterogeneous. Still, dose-finding/safety run-ins generally have a lower bar for a ‘positive’ interpretation than efficacy studies, since identifying a tolerable dose or manageable DLT profile can be enough. The Active Not Recruiting status suggests execution is largely complete, which reduces enrollment risk, but the passed primary completion date without disclosed results adds some disclosure uncertainty. Overall, the trial facts support modestly favorable YES odds, but not a high-conviction view because efficacy evidence is not described.

The primary endpoints are DLT and MTD from Part 1 dose escalation, which sets a relatively low bar for 'positive' results. Prior Phase 1 data (HLX26-001 and HLX26-002) showed no DLTs across all dose levels tested (60-1600mg), with manageable safety profiles and no new safety signals. This strongly suggests the DLT/MTD safety endpoint will be met. However, early efficacy signals were weak: in the Phase 1 combo study (HLX26-002), 0/8 evaluable patients achieved objective responses, with only 37.5% achieving stable disease. The broader LAG-3 landscape in NSCLC is mixed—RELATIVITY-104 showed only modest ORR improvement (51.3% vs 43.7%) when adding relatlimab to nivolumab+chemo, with benefit limited to PD-L1≥1% subgroups. The trial is past its primary completion date with no results disclosed, introducing some uncertainty about data quality or complications. The safety endpoint likely succeeds, but broader 'positive' interpretation encompassing efficacy remains uncertain given the weak early signals and competitive landscape challenges for LAG-3 in NSCLC.

This is a Phase 2 dose-finding study primarily evaluating safety endpoints (DLT and MTD) of HLX26 (anti-LAG-3) combined with Serplulimab (anti-PD-1) and chemotherapy in treatment-naive advanced NSCLC. Phase 2 dose-finding studies are designed to identify tolerable doses, making positive safety outcomes statistically likely. The combination targets two validated immune pathways (LAG-3 and PD-1) plus chemotherapy, which is scientifically rationale. However, the trial is 60 days overdue for primary completion, introducing execution risk. The primary endpoints focus on tolerability rather than efficacy, so 'positive' likely means acceptable safety profile. Given the study design's intent to find a tolerable dose and the established checkpoint inhibitor class, intrinsic probability favors positive results, though confidence is moderate due to operational delays and early-stage combination complexity.

This is a Phase 2 safety and dose-finding study (Part 1) for an anti-LAG-3 (HLX26) combo in 1L advanced NSCLC. The primary endpoints are DLT and MTD, not efficacy. The trial is 'Active Not Recruiting,' and the primary completion date has passed (-60 days), suggesting data collection is likely complete. Given the established safety profile of LAG-3/PD-1 combos (e.g., relatlimab + nivolumab) and chemotherapy's known tolerability, defining a safe dose is a relatively low bar. Sponsor Henlius has relevant experience with Serplulimab. The main risk is an unexpected safety signal, but the probability of successfully establishing MTD/DLT is moderately high.

Trial design features Part 1 dose-escalation (likely 3+3) to determine DLT and MTD for HLX26 (anti-LAG-3 mAb) + serplulimab (anti-PD-1) + chemotherapy in front-line advanced NSCLC, with assessment over 21 days post-first dose. Positive resolution probable if RP2D identified without prohibitive toxicity. Patient population is standard untreated Stage IV NSCLC, highly eligible and representative of real-world front-line setting. Endpoint quality excellent: DLT/MTD objective, standardized (typically Gr>=3 non-hematologic AEs, Gr>=4 hematologic), low subjectivity. Prior data supportive—serplulimab approved in NSCLC; LAG-3+PD-1 combos (e.g., relatlimab+nivolumab) + chemo show manageable safety in NSCLC trials, no class toxicity signals. Operational execution strong: Henlius (experienced, multiple IO approvals) in China enables fast accrual (active not recruiting, primary complete -60 days). Disclosure risk minimal—public sponsor (2696.HK), NCT-listed, top-line readout expected soon. Overall, safety met in >80% similar IO dose-finding trials.

This Phase 2 study (NCT05787613) evaluates HLX26 (anti-LAG-3) combined with serplulimab (anti-PD-1) and chemotherapy in first-line advanced NSCLC. The primary endpoint focuses on dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) determination, suggesting the immediate question resolves on safety/tolerability rather than efficacy superiority. LAG-3/PD-1 combination strategies have established precedent with relatlimab showing viability, and serplulimab has demonstrated efficacy in other indications. The trial has completed its primary completion date (estimated Feb 2026, now -60 days past) with status 'Active Not Recruiting,' indicating the primary safety endpoint data collection is likely concluded. Phase 1/2 dose-escalation safety studies typically succeed unless unexpected synergistic toxicity emerges. Given the manageable safety profiles of both antibody classes and the sponsor's established serplulimab data, probability of a 'positive' safety determination is favorable.

This Phase 2 trial of HLX26 (anti-LAG-3) plus Serplulimab (anti-PD-1) and chemotherapy in first-line advanced NSCLC has completed primary completion (est. Feb 2026, now 60 days past). The primary endpoints focus on safety (DLT, MTD) rather than efficacy, which typically yields higher success rates. Dual checkpoint inhibition with LAG-3/PD-1 is mechanistically sound—relatlimab/nivolumab is approved in melanoma. Serplulimab has demonstrated efficacy in NSCLC previously. The sponsor Henlius is an established Chinese biotech with execution track record. 'Active Not Recruiting' status suggests data collection/analysis ongoing, with no early termination signal. Phase 2 oncology safety trials with established PD-1 backbone generally resolve positively (~60-70%). No disclosure red flags evident. The main risk is unexpected toxicity from the triple combination or manufacturing issues, but this appears manageable given the 3-week DLT window has clearly passed.

The primary endpoints for this Phase 2 trial are Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) in Part 1, representing the safety run-in phase. For such designs, establishing an MTD or a recommended Phase 2 dose to proceed to the expansion phase constitutes a positive outcome. The dual blockade of LAG-3 (HLX26) and PD-1 (serplulimab) has already demonstrated an excellent safety profile in a prior Phase 1 solid tumor trial with zero DLTs observed at doses up to 1600 mg. Adding standard-of-care chemotherapy (carboplatin plus pemetrexed or paclitaxel) to this IO doublet is unlikely to produce synergistic, unmanageable acute toxicities, as similar triplet regimens have proven broadly tolerable in NSCLC. Furthermore, the trial's status of 'Active Not Recruiting' indicates that enrollment is complete, meaning the Part 1 safety run-in was successfully cleared without prohibitive toxicity, allowing the trial to progress. Given the purely safety-focused primary endpoints and the lack of overlapping severe toxicities between the study agents, the likelihood of a positive safety readout is exceptionally high.

The trial is a Phase 2 study evaluating the efficacy, safety, and tolerability of HLX26 combined with Serplulimab and chemotherapy in previously untreated advanced NSCLC patients. The use of combination therapy with a checkpoint inhibitor (Serplulimab) and a novel agent (HLX26) targeting LAG-3, a checkpoint molecule, suggests a potentially synergistic approach. The primary endpoint focuses on dose-limiting toxicity and maximum tolerated dose, which are standard for Phase 1/2 trials but also provide insight into the safety and potential efficacy of the combination. Given that the trial is active but not recruiting, it implies that the initial safety and efficacy signals are promising enough to proceed to further evaluation. The involvement of a reputable sponsor, Shanghai Henlius Biotech, and the specific targeting of NSCLC, a common and challenging cancer type, add to the optimism. However, the confidence is not higher due to the early-stage nature of the trial and the inherent uncertainties in translating Phase 2 results to overall positive outcomes.